CAS: 220519-07-3

Applications ABT 925 Fumerate is a dopamine D3 receptor antagonist that is used in the treatment of acute schizophrenia (1). References (1) Redden, L., et al.: J. Clin. Psychopharmacol, 31, 221 (2011)

ABT 925-d6 fumerate is a deuterated chemical compound, which serves as a stable isotope-labeled reagent. It is synthesized through the substitution of hydrogen atoms with deuterium in the fumerate moiety, offering increased stability for analytical applications. The incorporation of deuterium enhances the compound's resistance to metabolic degradation and allows for precise tracking in biological systems via mass spectrometry. This compound is employed extensively in metabolic studies and research applications where precise quantification of metabolic pathways is required. In particular, its utility in tracer studies enables scientists to dissect complex biochemical processes with high accuracy due to its distinguishable mass difference compared to non-deuterated analogs. ABT 925-d6 fumerate is instrumental in the analysis of metabolic flux and has applications across pharmacokinetics, drug metabolism studies, and biochemical pathway elucidation.

ABT-925/A-37203 is a selective DRD3 antagonist, with ~100x more affinity for D₃ over D₂, tested in schizophrenia.